Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Phosphodiesterase type 5 inhibitor abuse: a critical review.

Lowe G, Costabile R.

Curr Drug Abuse Rev. 2011 Jun;4(2):87-94. Review.

PMID:
21696344
[PubMed - indexed for MEDLINE]
2.

10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.

Lowe G, Costabile RA.

J Sex Med. 2012 Jan;9(1):265-70. doi: 10.1111/j.1743-6109.2011.02537.x. Epub 2011 Oct 24.

PMID:
22023666
[PubMed - indexed for MEDLINE]
3.

Phosphodiesterase 5 inhibitors for erectile dysfunction.

Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE.

Ann Pharmacother. 2005 Jul-Aug;39(7-8):1286-95. Epub 2005 Jun 7. Review.

PMID:
15941818
[PubMed - indexed for MEDLINE]
4.

2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.

Shindel AW.

J Sex Med. 2009 Sep;6(9):2352-64; quiz 2365-6. doi: 10.1111/j.1743-6109.2009.01447.x.

PMID:
19735356
[PubMed - indexed for MEDLINE]
5.

Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?

Aliferis K, Petropoulos IK, Farpour B, Matter MA, Safran AB.

Ophthalmologica. 2012;227(2):85-9. doi: 10.1159/000333824. Epub 2011 Dec 7.

PMID:
22156704
[PubMed - indexed for MEDLINE]
6.

The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.

Gökçe A, Halis F, Demirtas A, Ekmekcioglu O.

BJU Int. 2011 Apr;107(8):1274-7. doi: 10.1111/j.1464-410X.2010.09646.x. Epub 2010 Sep 7.

PMID:
21929518
[PubMed - indexed for MEDLINE]
7.

Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.

Azzouni F, Abu samra K.

J Sex Med. 2011 Oct;8(10):2894-903. doi: 10.1111/j.1743-6109.2011.02382.x. Epub 2011 Jul 19. Review.

PMID:
21771280
[PubMed - indexed for MEDLINE]
8.

Phosphodiesterase type 5 inhibitors: the day after.

Hatzimouratidis K, Hatzichristou D.

Eur Urol. 2007 Jan;51(1):75-88; discussion 89. Epub 2006 Aug 1. Review.

PMID:
16949200
[PubMed - indexed for MEDLINE]
9.

Internet-ordered viagra (sildenafil citrate) is rarely genuine.

Campbell N, Clark JP, Stecher VJ, Goldstein I.

J Sex Med. 2012 Nov;9(11):2943-51. doi: 10.1111/j.1743-6109.2012.02877.x. Epub 2012 Aug 27.

PMID:
22925379
[PubMed - indexed for MEDLINE]
10.

Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.

Kamenov ZA.

J Sex Med. 2011 Mar;8(3):851-64. doi: 10.1111/j.1743-6109.2010.02148.x. Epub 2010 Dec 8.

PMID:
21143421
[PubMed - indexed for MEDLINE]
11.

Phosphodiesterase inhibitors in Raynaud's phenomenon.

Levien TL.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1388-93. Epub 2006 Jul 11. Review.

PMID:
16835313
[PubMed - indexed for MEDLINE]
12.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
[PubMed - indexed for MEDLINE]
13.

Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.

Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D.

J Sex Med. 2005 Nov;2(6):848-55.

PMID:
16422809
[PubMed - indexed for MEDLINE]
14.

Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.

Gresser U, Gleiter CH.

Eur J Med Res. 2002 Oct 29;7(10):435-46. Review.

PMID:
12435622
[PubMed - indexed for MEDLINE]
15.

A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Hatzimouratidis K, Hatzichristou DG.

Drugs. 2005;65(12):1621-50. Review.

PMID:
16060698
[PubMed - indexed for MEDLINE]
16.

Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.

Fleshner N, Harvey M, Adomat H, Wood C, Eberding A, Hersey K, Guns E.

J Urol. 2005 Aug;174(2):636-41; discussion 641; quiz 801.

PMID:
16006928
[PubMed - indexed for MEDLINE]
17.

Phosphodiesterase 5 inhibitors in male sexual dysfunction.

Kuthe A.

Curr Opin Urol. 2003 Sep;13(5):405-10. Review.

PMID:
12917517
[PubMed - indexed for MEDLINE]
18.

Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.

Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, Fusco F.

J Sex Med. 2011 Dec;8(12):3418-32. doi: 10.1111/j.1743-6109.2011.02473.x. Epub 2011 Oct 13. Review.

PMID:
21995676
[PubMed - indexed for MEDLINE]
19.

Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.

Taylor J, Baldo OB, Storey A, Cartledge J, Eardley I.

BJU Int. 2009 May;103(10):1392-5. doi: 10.1111/j.1464-410X.2008.08328.x. Epub 2009 Jan 20.

PMID:
19154494
[PubMed - indexed for MEDLINE]
20.

Monitoring by LC-MS/MS of 48 compounds of sildenafil, tadalafil, vardenafil and their analogues in illicit health food products in the Korean market advertised as enhancing male sexual performance.

Lee JH, Kim NS, Han KM, Kim SH, Cho S, Kim WS.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(11):1849-57. doi: 10.1080/19440049.2013.826878. Epub 2013 Sep 2.

PMID:
23998781
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk